Skuldtech identifies new predictive markers for pancreatic cancer survival resulting from its proprietary technology platform
09-Nov-2012 -
Skuldtech, a genomic and pharmacogenomic company specialized in developing diagnostic tests, announced it has successfully used its technological platform to identify new biomarkers during a phase III clinical trial. This discovery made it possible to file a marketing authorization application ...
biomarkers
Gemcitabine
masitinib
+2